GENE ONLINE|News &
Opinion
Blog

2021-08-02| PartnerM&ASpecial

A Boom in High-Value M&A and Licensing Deals in the Exosome Field

by GeneOnline
Share To
During the pandemic, the growth of most biopharma businesses had slowed down, except for COVID-19 vaccines and therapies. Yet, exosome-related deals have thrived even under such difficult circumstances, shedding light on the tremendous potential of startups and ground-breaking technologies.  Who are the buyers? And who are the rising stars?

Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough

GO Prime with only $1.49 now

LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top